Halozyme Therapeutics, Inc. — Q2 2012 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2012; financial statements are unaudited. Halozyme is a biopharmaceutical company developing enzyme-based therapies and its Enhanze drug-delivery platform, through proprietary programs and collaborations. Hylenex recombinant was its marketed product, but product sales remained limited.
Financial performance and position
| Metric | Three months ended June 30, 2012 | Six months ended June 30, 2012 | Comparable 2011 period |
|---|---|---|---|
| Total revenue | $7.76 million | $15.20 million | $23.19 million and $30.73 million, respectively |
| Net income (loss) | $(14.02) million | $(29.14) million | $3.12 million income and $(6.52) million loss, respectively |
| Net loss per share | $(0.13) | $(0.27) | $0.03 income and $(0.06) loss per share, respectively |
| Operating cash flow | Not presented for quarter | $(33.11) million | $(7.35) million for six months |
| Cash and cash equivalents | $102.04 million at June 30, 2012 | $52.83 million at December 31, 2011 |
- Q2 product sales were $525,000; collaborative-agreement revenue was $7.23 million. Six-month product sales were $712,000 and collaboration revenue was $14.49 million.
- Operating expenses were $21.81 million in Q2 and $44.39 million for the first half. Research and development was $16.08 million and $31.97 million, respectively; selling, general and administrative expense was $5.58 million and $12.20 million.
- At June 30, total assets were $121.75 million, total liabilities were approximately $52.51 million, and stockholders’ equity was $69.23 million. The filing reports no borrowings; liabilities primarily included deferred revenue and operating accruals.
- Current assets were $119.73 million versus current liabilities of $16.15 million. Deferred revenue totaled $42.04 million, including $41.79 million under collaborations.
- Financing activities provided $83.03 million in the first half, principally $81.48 million net proceeds from a February public offering. The offering issued 7.82 million shares at $10.61 per share. Shares outstanding were 112.69 million at June 30.
Changes versus prior comparable periods
- Q2 revenue fell 67% year over year and first-half revenue fell 51.0%, mainly because the 2011 periods included $18 million of upfront ViroPharma and Intrexon license fees that were recognized then.
- First-half collaboration reimbursements for research and development services rose to $6.8 million from $2.9 million, primarily due to increased PH20 API shipments to Roche and Baxter. Timing of partner-requested services and shipments makes this revenue variable.
- First-half research and development expense rose 10% to $32.0 million, while SG&A increased 53% to $12.2 million, including greater compensation and commercial costs following the Hylenex relaunch. Lower ultrafast-insulin clinical-trial spending partly offset R&D increases.
- The first-half net loss widened to $29.1 million from $6.5 million. The comparison reflects lower collaboration revenue and increased operating expenses.
- Cash rose by $49.2 million from year-end, supported by the equity offering despite $33.1 million of operating cash use.
Outlook, risks and unusual items
- Management expected 2012 net cash burn of approximately $55–$60 million and said cash and cash equivalents should fund operations for at least the next 12 months. It also stated revenue was not expected to fund operations for several years. These are forward-looking estimates, not guarantees.
- Management expected 2012 R&D, SG&A and product-sales costs to rise, citing expanded development and manufacturing activity and Hylenex commercialization.
- Material regulatory development disclosed after quarter-end: On August 1, 2012, the FDA’s CBER issued a complete response letter for Baxter’s HyQ application, requesting additional preclinical data concerning non-neutralizing antibodies to rHuPH20 and possible reproductive, developmental and fertility effects. CBER requested that patients no longer be dosed with rHuPH20 in the Baxter program pending further data. The filing also reported a temporary hold on the ViroPharma/rHuPH20 study. The companies expected additional work to delay review and approval timelines.
- Halozyme said FDA’s CDER had reviewed the issue and confirmed no action was needed against Hylenex or clinical programs under the Hylenex IND, including proprietary programs. The company and Roche did not then expect the concerns to affect their other programs, but acknowledged future regulatory uncertainty.
- Key risks include dependence on rHuPH20 across programs, clinical and regulatory failure or delay, reliance on contract manufacturers, partner performance and termination rights, limited product revenue, ongoing losses, and potential need for further capital. Further equity financing could dilute shareholders.
- Hylenex distributor shipments are recorded as deferred revenue until sell-through is confirmed; because of limited sales history and lengthy return rights, the company could not yet reliably estimate returns and chargebacks. This makes reported product revenue sensitive to sell-through and estimates.
- The company reported no legal proceedings expected by management to have a material adverse effect. Disclosure controls were concluded effective as of June 30, 2012.
Most important facts for investors to verify
- Updates on the FDA’s requested preclinical work and the status of Baxter’s HyQ and ViroPharma clinical programs.
- Whether the stated cash runway and 2012 burn estimate remain realistic as clinical, manufacturing and commercialization spending changes.
- Partner program progress, milestone timing, partner-requested reimbursements, and any partner decisions to reduce or terminate programs.
- Hylenex distributor sell-through, deferred revenue, return and chargeback estimates, and whether product sales grow as expected.
- Potential financing needs and dilution, given continuing losses and negative operating cash flow.